Asset Details
Do you wish to reserve the book?
PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia
Do you wish to request the book?
PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia
2016
Overview
The DNA methyltransferases DNMT3A and DNMT3B are primarily responsible for de novo methylation of specific cytosine residues in CpG dinucleotides during mammalian development. While loss-of-function mutations in DNMT3A are highly recurrent in acute myeloid leukemia (AML), DNMT3A mutations are almost never found in AML patients with translocations that create oncogenic fusion genes such as PML-RARA, RUNX1-RUNX1T1, and MLL-AF9. Here, we explored how DNMT3A is involved in the function of these fusion genes. We used retroviral vectors to express PML-RARA, RUNX1-RUNX1T1, or MLL-AF9 in bone marrow cells derived from WT or DNMT3A-deficient mice. Additionally, we examined the phenotypes of hematopoietic cells from Ctsg-PML-RARA mice, which express PML-RARA in early hematopoietic progenitors and myeloid precursors, with or without DNMT3A. We determined that the methyltransferase activity of DNMT3A, but not DNMT3B, is required for aberrant PML-RARA-driven self-renewal ex vivo and that DNMT3A is dispensable for RUNX1-RUNX1T1- and MLL-AF9-driven self-renewal. Furthermore, both the PML-RARA-driven competitive transplantation advantage and development of acute promyelocytic leukemia (APL) required DNMT3A. Together, these findings suggest that PML-RARA requires DNMT3A to initiate APL in mice.
Publisher
American Society for Clinical Investigation
Subject
/ Cancer
/ Cloning
/ Core Binding Factor Alpha 2 Subunit - physiology
/ DNA
/ DNA (Cytosine-5-)-Methyltransferases - physiology
/ Enzymes
/ Genomes
/ Grants
/ Leukemia
/ Leukemia, Promyelocytic, Acute - etiology
/ Mice
/ Mutation
/ Oncogene Proteins, Fusion - physiology
/ Proteins
/ Software
/ Studies
